List of Excipients in Branded Drug CORTISONE ACETATE

Generic Drugs Containing CORTISONE ACETATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	cortisone acetate	0143-1202	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	cortisone acetate	0143-1202	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	cortisone acetate	0143-1202	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CORTISONE ACETATE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
2	CELLULOSE, MICROCRYSTALLINE

Cortisone Acetate Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Cortisone acetate is an established, low-cost corticosteroid with limited protection from active-ingredient patents, regulatory exclusivity, or proprietary delivery technology. The commercial opportunity is therefore formulation-led. Manufacturers can compete through excipient safety, dose uniformity, swallowability, pediatric usability, supply reliability, and differentiated packaging rather than through the molecule itself.

The strongest opportunities are low-dose immediate-release tablets, orally disintegrating tablets, liquid suspensions, preservative-controlled compounded products, and region-specific products that address lactose, sugar, gluten, or animal-derived excipient concerns.

What is cortisone acetate and how is it used?

Cortisone acetate is an oral glucocorticoid prodrug that is converted to hydrocortisone in vivo. It is used for corticosteroid replacement and inflammatory or allergic conditions when clinically appropriate. Approved labeling has historically covered endocrine, rheumatic, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, and hematologic indications, although current product availability and labeling vary by jurisdiction. [1]

Cortisone acetate is distinct from hydrocortisone acetate and prednisone. Its commercial positioning depends on the indication, dose, clinical preference, and availability of alternative corticosteroids.

Core product characteristics

Attribute	Cortisone acetate
Active ingredient	Cortisone acetate
Therapeutic class	Glucocorticoid
Common oral strengths	5 mg, 10 mg, and 25 mg tablets in historical and current generic markets
Typical dosage form	Immediate-release tablet
Administration	Primarily oral; product availability varies by market
Regulatory status	Established small-molecule drug
Biosimilar pathway	Not applicable
Primary development opportunity	Excipient and dosage-form differentiation
Main commercial constraint	Low price and competition from hydrocortisone, prednisone, and other corticosteroids

Cortisone acetate has a narrow product-specific commercial niche. Patients requiring physiologic replacement may have different dose requirements from patients treated for inflammatory conditions. This increases the value of accurate low-dose manufacturing and flexible strength portfolios.

What excipients are used in cortisone acetate tablets?

Cortisone acetate tablets generally use conventional immediate-release excipients. The exact composition depends on the manufacturer and strength. Typical excipient categories include fillers, binders, disintegrants, lubricants, glidants, and coating materials.

Potential excipient classes include:

Function	Candidate excipient classes	Development considerations
Diluent	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Controls tablet size, compressibility, and patient tolerability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Critical for rapid release at low drug loading
Lubricant	Magnesium stearate, sodium stearyl fumarate	Excessive use may slow dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Sweetener or flavor	Sucralose, saccharin sodium, mannitol, flavor systems	Relevant to orally disintegrating and pediatric products
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Supports identification, handling, and taste masking

The final selection must be supported by formulation development, impurity assessment, dissolution testing, stability data, and regulatory review. FDA's Inactive Ingredient Database can support precedent analysis, but prior use in another product does not eliminate the need to assess concentration, route, population, and dosage form. [2]

Which excipient risks matter most?

The principal risks are not chemical novelty. They are dose uniformity, dissolution, manufacturability, and patient acceptability.

Cortisone acetate tablets may contain a relatively small quantity of active ingredient compared with the total tablet mass. Low-dose products therefore require careful control of:

• Active ingredient segregation during blending
• Particle-size distribution
• Content uniformity
• Over-lubrication
• Compression-force variability
• Blend sampling strategy
• Cleaning validation and cross-contamination control

A direct-compression process may reduce manufacturing steps, but it requires suitable powder flow and compressibility. Wet granulation can improve content uniformity and handling but increases process complexity and exposure to moisture. The preferred process depends on the active pharmaceutical ingredient's particle size, density, flow, and stability profile.

What is the best excipient strategy for cortisone acetate?

The most defensible strategy is a modular platform that supports several patient and market segments without changing the active ingredient.

Standard immediate-release tablet

A conventional tablet remains the lowest-risk commercial product. A formulation based on microcrystalline cellulose or lactose, a superdisintegrant, a low-level lubricant, and a conventional film coat can support efficient manufacturing and broad market access.

Commercial advantages include:

• Straightforward development
• Established regulatory precedent
• Low manufacturing cost
• Compatibility with generic substitution
• Broad distribution through retail and institutional channels

The principal weakness is limited differentiation. A standard tablet is likely to compete primarily on price, supply reliability, and tender performance.

Lactose-free formulation

A lactose-free tablet can target patients with lactose intolerance, excipient avoidance preferences, and selected institutional formularies. Microcrystalline cellulose, mannitol, or dibasic calcium phosphate may replace lactose, subject to development data.

The commercial value is greater when the product is also:

• Gluten-free
• Dye-free
• Low in allergens
• Suitable for halal or kosher requirements where relevant
• Packaged in moisture-protective blisters

A lactose-free label alone is unlikely to support substantial pricing power. It can, however, improve formulary access and support a differentiated product family.

Orally disintegrating tablet

An orally disintegrating tablet could address patients with dysphagia, older adults, pediatric patients, and patients who have difficulty taking conventional tablets. Mannitol-based systems are often useful for mouthfeel, while crospovidone or croscarmellose sodium can support rapid disintegration.

Development priorities include:

• Short disintegration time
• Low friability
• Adequate mechanical strength
• Taste masking
• Moisture protection
• Dose uniformity at low strength
• Packaging that protects individual units

The main regulatory risk is proving that the product is sufficiently comparable to the reference product. A novel disintegration profile, altered absorption, or different dosing instructions could increase the need for clinical or pharmacokinetic support under a 505(b)(2) pathway rather than a conventional ANDA pathway. [3]

Pediatric liquid or suspension

A liquid product could improve dosing flexibility for pediatric and geriatric patients. A suspension may be more practical than a true solution because cortisone acetate has limited aqueous solubility.

The excipient system may require:

• Suspending agents
• Wetting agents
• Buffering agents
• Sweeteners
• Flavors
• Preservatives
• Antifoaming agents
• A robust redispersibility profile

Key risks include sedimentation, caking, dose nonuniformity after storage, preservative effectiveness, microbial growth, and palatability. Sugar-free and alcohol-free versions could expand use in pediatric and diabetes-sensitive populations.

A liquid product has more differentiation potential than a standard tablet but also carries higher development, packaging, and stability costs.

What patents protect cortisone acetate products?

Cortisone acetate's active-ingredient patent estate is effectively historic. The molecule was introduced decades ago, and any original composition-of-matter, basic formulation, or early method-of-use patents would have expired under modern patent-term rules.

Current patent and exclusivity position

Protection category	Commercial assessment
Original active-ingredient patents	Expired
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not inherent to the product
Biosimilar exclusivity	Not applicable
Core tablet formulation patents	No material barrier expected for conventional products
Method-of-use patents	Historic indications are generally vulnerable to expiration and invalidity challenges
New ODT or liquid patents	Potentially available, but must claim non-obvious technical features
Trade secrets	Relevant to process parameters, granulation, coating, and packaging

No patent-based exclusivity should be assumed for a conventional cortisone acetate tablet. A new patent position would need to rely on a genuinely differentiated formulation, manufacturing process, dosing regimen, or device. A patent that merely substitutes one routine excipient for another would face obviousness and enablement risk.

The relevant U.S. patent term for a later-filed utility patent is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments. [4]

When does cortisone acetate lose exclusivity?

Cortisone acetate has already lost the exclusivity associated with its original development. There is no expected NCE exclusivity period for a new generic cortisone acetate product, and the molecule is not a biologic.

A sponsor developing a conventional tablet would normally seek an abbreviated pathway if an appropriate reference product and regulatory basis exist. A sponsor developing a novel liquid, ODT, modified-release product, or other differentiated formulation may need to assess the 505(b)(2) pathway. FDA approval requirements depend on the proposed product, reference product, dosage form, labeling, and evidence package. [3]

What is the Orange Book status of cortisone acetate?

The Orange Book is relevant to approved prescription drug products, therapeutic equivalence evaluations, patent listings, and exclusivity. Cortisone acetate's practical Orange Book risk is expected to be low because its principal commercial products are old generic products without a meaningful surviving patent estate.

A sponsor should distinguish among:

• Historical brand or NDA records
• Currently marketed generic products
• Discontinued products
• Patent listings associated with a specific NDA
• Therapeutic-equivalence codes for individual products

An old NDA record does not prove that a product remains commercially available. Conversely, the absence of an active patent listing does not eliminate regulatory or manufacturing risks. Orange Book records should be reviewed at the product level before an ANDA or 505(b)(2) filing. [5]

Are there Paragraph IV challenges for cortisone acetate?

Paragraph IV litigation is unlikely to be a central issue for a conventional cortisone acetate product because the original patent estate is old and no major active patent barrier is expected.

The more relevant legal risks are:

• Patent disputes over a newly developed ODT or liquid formulation
• Trade-dress or labeling disputes
• Allegations involving manufacturing process patents
• Exclusivity or certification issues tied to a specific reference product
• Commercial disputes over therapeutic-equivalence ratings

A Paragraph IV strategy would have limited value unless an active, listed patent blocks approval of a specific reference product. The absence of a live patent barrier shifts the competitive focus toward ANDA timing, manufacturing readiness, supply-chain execution, and reimbursement.

Which companies are challenging or competing with cortisone acetate?

Competition comes from generic manufacturers and from alternative corticosteroids rather than from biosimilar developers.

Direct competitors

Direct competitors may include manufacturers of:

• Cortisone acetate tablets
• Cortisone acetate compounded liquids
• Other cortisone acetate presentations, where approved
• Authorized or legacy branded products in selected markets

The number of active suppliers varies by country and changes as manufacturers discontinue low-volume products.

Therapeutic competitors

Cortisone acetate competes with:

• Hydrocortisone
• Prednisone
• Prednisolone
• Methylprednisolone
• Dexamethasone
• Fludrocortisone in selected replacement settings

Hydrocortisone is particularly important in endocrine replacement because clinicians may prefer its pharmacologic profile, dosing flexibility, and product availability. Prednisone and prednisolone may be preferred in inflammatory conditions. A cortisone acetate product therefore needs a clear prescribing rationale or a supply and formulation advantage.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

A commercial program must control:

• Low-dose content uniformity
• API particle-size variability
• Blend segregation
• Tablet weight variation
• Dissolution across strengths
• Moisture and temperature exposure
• Cleaning validation
• Packaging stability
• Supplier qualification for excipients and API

Corticosteroid manufacturing also requires controls against potent-compound carryover, worker exposure, and cross-contamination. These controls can increase facility and validation costs even when the product itself is inexpensive.

Geographic coverage

A formulation may be commercially attractive in one region and impractical in another because of:

• Different reference products
• Country-specific excipient restrictions
• Local pediatric requirements
• Separate pharmacopoeial standards
• Variations in prescription status
• Tender-based pricing
• Local manufacturing or serialization requirements

A global product platform should therefore maintain an excipient-neutral core formulation and allow regional adjustments in flavor, coloring, sugar content, packaging, and labeling.

How strong is the patent estate for cortisone acetate?

The patent estate is weak for conventional products and potentially moderate for a technically differentiated delivery system.

Product concept	Patent strength	Commercial defensibility
Conventional immediate-release tablet	Low	Price, quality, and supply
Lactose-free tablet	Low to moderate	Labeling and patient segment
ODT	Moderate if technically differentiated	Taste, disintegration, packaging, clinical usability
Pediatric suspension	Moderate	Stability, redispersibility, dosing accuracy
Modified-release product	Potentially moderate to strong	Requires substantial development and clinical support
Novel combination product	Potentially strong	Depends on clinical rationale and patent claims
Manufacturing process	Moderate	Useful if difficult to design around

A sponsor should avoid relying on a single formulation patent. The strongest protection would combine composition claims, process claims, use claims where available, device or packaging claims, and trade-secret controls over manufacturing parameters.

What commercial opportunities exist for cortisone acetate?

The most credible opportunities are:

1. A reliable low-cost generic tablet portfolio covering 5 mg, 10 mg, and 25 mg strengths where commercially supported.
2. A lactose-free, dye-free, gluten-free product for institutional and patient-preference markets.
3. An ODT for dysphagia and pediatric use.
4. A sugar-free oral suspension with accurate dose measurement.
5. Unit-dose blister packaging for adherence, travel, and institutional administration.
6. Contract manufacturing or private-label supply in markets with limited corticosteroid availability.
7. A regional product optimized for local formularies and tender requirements.
8. A formulation platform that supports both conventional tablets and pediatric liquid products.

Revenue potential is likely to depend more on volume, market access, shortage management, and manufacturing cost than on premium pricing. The most defensible strategy is to develop a low-cost base product and add one differentiated presentation with a clear patient or payer benefit.

Key Takeaways

• Cortisone acetate is an old small-molecule corticosteroid with no meaningful original patent or exclusivity barrier.
• The commercial opportunity is formulation-led rather than molecule-led.
• Low-dose content uniformity, dissolution, and manufacturing control are central technical risks.
• Lactose-free tablets, ODTs, and pediatric suspensions offer the clearest differentiation.
• A standard tablet is most suitable for ANDA-style low-cost competition where a valid reference pathway exists.
• A novel liquid or ODT may require a 505(b)(2) analysis.
• Biosimilar risk is not relevant because cortisone acetate is a small molecule.
• Patent protection for a new product would need technically specific, non-obvious claims.
• Manufacturing, supply continuity, packaging, and therapeutic competition are more significant than Paragraph IV litigation.
• Hydrocortisone, prednisone, and prednisolone are major commercial alternatives.

FAQs

Is cortisone acetate the same as hydrocortisone?

No. Cortisone acetate is converted in the body to hydrocortisone. They are related corticosteroids but are not the same active ingredient and are not automatically substitutable on a milligram-for-milligram basis.

Can cortisone acetate be formulated as a liquid?

Yes. A suspension is generally more practical than a simple aqueous solution because the active ingredient has limited water solubility. The product would require validated dose uniformity, redispersibility, microbial control, and stability.

Is a lactose-free cortisone acetate tablet patentable?

It may be patentable only if the formulation produces a non-obvious technical result and satisfies novelty, inventive-step, written-description, and enablement requirements. Lactose substitution alone would usually provide limited patent strength.

Does cortisone acetate have biosimilar competition?

No. Biosimilars apply to biologic products. Cortisone acetate is a chemically synthesized small molecule and competes through generic and alternative-drug pathways.

What is the highest-value formulation opportunity?

An orally disintegrating or pediatric liquid product with validated dosing, acceptable taste, moisture-protective packaging, and a clear regulatory pathway offers greater differentiation than another conventional immediate-release tablet.

References

1. U.S. National Library of Medicine. (n.d.). Cortisone acetate tablet prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).
4. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.